Vivo Capital LLC Sells 2,222,222 Shares of Aclaris Therapeutics, Inc. $ACRS

Vivo Capital LLC lessened its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,666,666 shares of the biotechnology company’s stock after selling 2,222,222 shares during the quarter. Aclaris Therapeutics makes up about 2.1% of Vivo Capital LLC’s portfolio, making the stock its 16th biggest position. Vivo Capital LLC’s holdings in Aclaris Therapeutics were worth $25,000,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. XTX Topco Ltd bought a new position in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $34,000. R Squared Ltd bought a new stake in shares of Aclaris Therapeutics in the fourth quarter worth $37,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aclaris Therapeutics in the second quarter worth $48,000. BNP Paribas Financial Markets boosted its holdings in Aclaris Therapeutics by 59.0% during the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 9,894 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in Aclaris Therapeutics during the fourth quarter worth $52,000. Institutional investors own 98.34% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on ACRS shares. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Wednesday, June 24th. Lifesci Capital initiated coverage on Aclaris Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $13.00 target price on the stock. Wedbush upped their target price on Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research report on Tuesday, May 5th. They set a “buy” rating and a $12.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $11.50.

Aclaris Therapeutics Trading Up 3.9%

NASDAQ ACRS opened at $5.32 on Friday. The firm has a market capitalization of $742.99 million, a P/E ratio of -9.50 and a beta of 0.76. The firm’s fifty day moving average price is $4.97 and its two-hundred day moving average price is $4.20. Aclaris Therapeutics, Inc. has a 1 year low of $1.46 and a 1 year high of $5.88.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $2.00 million during the quarter, compared to the consensus estimate of $1.32 million. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%. On average, research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.